Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Wegovy is a pure GLP-1 receptor agonist containing semaglutide, the same molecule as Ozempic
- It was the first FDA-approved GLP-1 medication specifically labeled for chronic weight management in adults (June 2021)
- The SELECT cardiovascular outcome trial led to an expanded indication in March 2024 for cardiovascular risk reduction in patients with established CV disease and overweight or obesity
- Mean weight loss in STEP 1 was about 14.9 percent at the 2.4 mg weekly dose over 68 weeks
- An adolescent indication for ages 12 and older was added in December 2024 based on STEP TEENS data
Direct answer
Yes, Wegovy is a GLP-1 medication. Specifically, it is a pure glucagon-like peptide-1 receptor agonist. The active ingredient is semaglutide, the same molecule found in Ozempic, but Wegovy is dosed higher and labeled for chronic weight management. It activates only the GLP-1 receptor, unlike tirzepatide-based Zepbound which also activates the GIP receptor.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The clean yes, with context
- Semaglutide at the molecular level
- Why Wegovy and Ozempic are separate products
- The STEP clinical trial program
- SELECT and the cardiovascular indication
- The adolescent approval and STEP TEENS data
- Dosing schedule and titration
- Side effects in obesity populations
- Cost, coverage, and the access landscape
- Compounded semaglutide and the FDA's position
- Contrary view: is Wegovy still first-line in 2026?
- Decision framework
- FAQ
- Sources
The clean yes, with context
Wegovy is unambiguously a GLP-1 medication. The active ingredient, semaglutide, activates only the GLP-1 receptor. There is no GIP component, no glucagon receptor component, no second receptor in the mechanism. This makes Wegovy a pure GLP-1 RA in the strict pharmacology sense.
The clean classification matters because Wegovy is the cleanest example of the GLP-1 mechanism applied to obesity. The trials, the cardiovascular outcomes, the regulatory pathway, and the patient experience all reflect the pure GLP-1 framework without the complicating factor of dual receptor activation.
If you want to understand how GLP-1 medications work for weight loss, Wegovy is the prototypical example. Other GLP-1 RAs for obesity (Saxenda) and dual agonists for obesity (Zepbound) build from or diverge from the Wegovy template.
Semaglutide at the molecular level
Semaglutide is a 31 amino acid peptide modeled on human GLP-1. It differs from native GLP-1 at two positions and carries a C18 fatty diacid side chain attached via a linker. These modifications give the molecule three useful properties:
- Resistance to DPP-4. The substitution at position 8 (Aib for Ala) blocks the enzyme that degrades native GLP-1 within minutes.
- Albumin binding. The fatty acid chain binds reversibly to albumin in the blood, dramatically extending circulation time.
- Receptor selectivity. Semaglutide binds the GLP-1 receptor with high affinity and does not activate other incretin receptors.
The half-life of semaglutide in humans is about 165 hours, or roughly seven days. That allows once-weekly subcutaneous dosing. Plasma levels reach steady state after four to five weekly doses.
The molecule was developed by Novo Nordisk during the 2000s and 2010s as a successor to liraglutide. Where liraglutide required daily dosing, semaglutide moved to weekly. The clinical advantage was significant for patient adherence and convenience.
Why Wegovy and Ozempic are separate products
Both contain semaglutide. They differ in approved indication, maximum dose, titration schedule, and pen design.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Approved indication | Chronic weight management; CV risk reduction in overweight/obese adults with CVD | Type 2 diabetes; CV risk reduction in patients with diabetes and established CVD |
| Maximum dose | 2.4 mg weekly | 2.0 mg weekly |
| Titration schedule | 16-week titration to 2.4 mg | 4-week minimums between dose steps to 2.0 mg |
| Pen design | Single-dose autoinjector | Multi-dose disposable pen |
| Approval year | 2021 | 2017 |
The split allows separate clinical trial pathways, separate insurance billing codes, and separate prior-authorization criteria. It also reflects the dosing reality: 2.4 mg produces more weight loss than 2.0 mg, and obesity trials use the higher dose.
The dual-product structure created some confusion. Patients prescribed Ozempic off-label for weight loss were sometimes underdosed compared with what they would receive on Wegovy. The structure also created two parallel supply chains, both of which faced shortages during 2022 to 2024.
The STEP clinical trial program
Wegovy's approval rested on the STEP (Semaglutide Treatment Effect in People with obesity) trial program. The major trials:
STEP 1 (Wilding et al., New England Journal of Medicine 2021). Semaglutide 2.4 mg vs placebo in adults with obesity or overweight with at least one comorbidity, but without diabetes. Mean weight loss at 68 weeks: 14.9 percent vs 2.4 percent placebo. About 86 percent of patients on semaglutide lost at least 5 percent body weight, and about one-third lost at least 20 percent.
STEP 2. Semaglutide in adults with obesity and type 2 diabetes. Weight loss was somewhat lower than in non-diabetic populations but still significant: 9.6 percent vs 3.4 percent placebo at 68 weeks.
STEP 3. Semaglutide plus intensive behavioral therapy. Both arms received intensive lifestyle support. Adding semaglutide produced 16.0 percent weight loss vs 5.7 percent on intensive behavioral therapy alone.
STEP 4 (Rubino et al., JAMA 2021). Withdrawal trial. Patients took semaglutide for 20 weeks, then were randomized to continue or switch to placebo. The continuing group lost additional weight; the placebo group regained substantial weight by 68 weeks. The contrast established the chronic nature of obesity treatment.
STEP 5. Two-year semaglutide trial. Demonstrated maintained weight loss with continued treatment, with weight loss plateau around month 12 to 16 and stable weight thereafter.
STEP 8 (Rubino et al., JAMA 2022). Direct head-to-head against liraglutide 3.0 mg. Semaglutide produced significantly more weight loss than liraglutide.
The cumulative dataset supported FDA approval and shaped the clinical understanding of GLP-1-based obesity treatment.
SELECT and the cardiovascular indication
The SELECT trial (Lincoff et al., New England Journal of Medicine 2023) was a landmark study. It enrolled adults with established cardiovascular disease and overweight or obesity but without type 2 diabetes. Patients were randomized to semaglutide 2.4 mg or placebo and followed for cardiovascular outcomes.
The primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was reduced by 20 percent over a median follow-up of 39.8 months. The result was statistically robust and clinically meaningful.
The FDA approved an expanded indication for Wegovy in March 2024: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. This made Wegovy the first weight-management medication with a cardiovascular benefit indication.
The cardiovascular finding has implications beyond obesity treatment. Wegovy can now be appropriately prescribed for cardiovascular risk reduction even in patients whose weight is not their primary concern, if they meet the criteria of established CVD and overweight/obesity.
The adolescent approval and STEP TEENS data
STEP TEENS (Weghuber et al., New England Journal of Medicine 2022) tested semaglutide 2.4 mg in adolescents aged 12 to 17 with obesity. Mean BMI reduction at 68 weeks was 16.1 percent on semaglutide vs 0.6 percent gain on placebo. The trial supported the FDA's December 2024 approval of Wegovy for chronic weight management in adolescents 12 and older with BMI at or above the 95th percentile for age and sex.
The adolescent indication was clinically important because pediatric obesity prevalence increased substantially through the 2010s and early 2020s, and pharmacological options for adolescents were limited. The American Academy of Pediatrics 2023 guidelines included anti-obesity medications as part of comprehensive treatment for adolescents with obesity, and the Wegovy approval gave pediatric clinicians a labeled option.
The pediatric use carries additional considerations: growth and development monitoring, transition planning to adult care, and family-based behavioral support. Long-term safety data in pediatric populations are still accumulating.
Dosing schedule and titration
Wegovy is dosed once weekly by subcutaneous injection. The titration schedule:
- Month 1: 0.25 mg weekly
- Month 2: 0.5 mg weekly
- Month 3: 1.0 mg weekly
- Month 4: 1.7 mg weekly
- Month 5 and beyond: 2.4 mg weekly (maintenance dose)
If a patient cannot tolerate the next planned dose, the prior dose may be maintained for an additional four weeks before another titration attempt. Some patients stabilize below 2.4 mg if they achieve clinical response or cannot tolerate higher doses.
Each Wegovy pen contains a single weekly dose. Injection sites rotate among abdomen, thigh, and upper arm. The pen mechanism is designed for self-administration.
Side effects in obesity populations
The STEP 1 trial reported the following common adverse events on semaglutide 2.4 mg:
- Nausea: 44 percent (vs 16 percent placebo)
- Diarrhea: 32 percent (vs 16 percent placebo)
- Vomiting: 25 percent (vs 7 percent placebo)
- Constipation: 24 percent (vs 11 percent placebo)
- Abdominal pain: 20 percent (vs 10 percent placebo)
- Headache: 14 percent (vs 11 percent placebo)
- Fatigue: 11 percent (vs 6 percent placebo)
Most events were mild to moderate, occurred during dose escalation, and improved as patients adjusted to higher doses. Discontinuation due to GI events was about 4.5 percent.
Wegovy carries the standard class warnings: boxed warning for medullary thyroid carcinoma (contraindicated in patients with personal or family history of MTC or MEN2 syndrome), acute pancreatitis, acute gallbladder disease, hypoglycemia in patients on insulin or insulin secretagogues, acute kidney injury (typically from dehydration), hypersensitivity reactions, diabetic retinopathy complications in patients with pre-existing retinopathy, increased heart rate, suicidal behavior and ideation (monitoring recommended), and pulmonary aspiration during anesthesia (consider perioperative discontinuation).
Cost, coverage, and the access landscape
Wegovy's list price in 2026 sits around $1,349 per month. Insurance coverage varies widely. Most commercial plans require prior authorization with documentation of BMI criteria and previous lifestyle attempts. Medicare Part D historically does not cover medications for weight loss, although the SELECT cardiovascular indication created a partial pathway: Wegovy can be covered when prescribed specifically for cardiovascular risk reduction in eligible patients.
Novo Nordisk launched a self-pay program in 2024 offering Wegovy at approximately $499 per month for cash-paying patients without insurance coverage. The program uses single-dose vials rather than autoinjector pens, similar to Eli Lilly's LillyDirect channel for Zepbound.
Patient access remains uneven. Patients in plans without obesity coverage often face the choice between paying out of pocket, switching to a different employer plan, or using off-label diabetes coverage for Ozempic (which is not the FDA-approved option for weight loss).
Compounded semaglutide and the FDA's position
During the FDA-declared semaglutide shortage (March 2022 through February 2025), 503A compounding pharmacies prepared compounded semaglutide for individual patients. Telehealth platforms scaled rapidly to provide access. Compounded semaglutide became a major route of obesity treatment during this window.
The FDA removed semaglutide from the shortage list in February 2025. Compounding under shortage rules ended, with a transition period for in-process prescriptions. The FDA position is that compounded semaglutide is not Wegovy, is not FDA-approved, and should not be marketed as equivalent.
Compounded semaglutide continues to exist outside the shortage pathway through 503A personalized prescribing for specific clinical situations (for example, a documented intolerance to commercial inactive ingredients or a need for a non-commercial dose). Volume is substantially lower than during 2023.
Contrary view: is Wegovy still first-line in 2026?
The clinical landscape has shifted since Wegovy's 2021 approval. Arguments that Wegovy may no longer be optimal first-line therapy:
First, Zepbound produces more weight loss in head-to-head data. SURMOUNT-1 vs STEP 1 comparison and the direct SURMOUNT-5 head-to-head favored tirzepatide. Patients who could tolerate either drug might achieve better results on Zepbound.
Second, Zepbound now has the OSA indication. Patients with both obesity and OSA may be better served by tirzepatide for the dual benefit.
Third, tirzepatide's manufacturing capacity expanded faster than semaglutide's. By late 2024, Zepbound was more readily available in many markets than Wegovy had been at comparable timepoints after launch.
The counterarguments:
SELECT gave Wegovy a cardiovascular indication that tirzepatide does not yet have. For patients with established CVD, Wegovy has the stronger labeled evidence base for cardiovascular benefit.
STEP TEENS gave Wegovy a pediatric indication. Zepbound is not approved in adolescents as of May 2026.
Wegovy's longer track record provides more accumulated safety data. Tirzepatide is newer; rare adverse events may emerge with longer use.
The reasonable middle position: Wegovy and Zepbound are both reasonable first-line choices. The decision depends on patient comorbidities, age, cardiovascular history, sleep apnea status, insurance coverage, and individual preference.
Decision framework
If you have established cardiovascular disease and overweight or obesity:
- Wegovy has the FDA-approved cardiovascular indication based on SELECT.
- This is one of the few obesity medications with cardiovascular outcome data.
- Discuss with your provider whether Wegovy fits your cardiovascular risk profile.
If you are an adolescent or have an adolescent child meeting criteria:
- Wegovy is FDA-approved for ages 12 and older. Zepbound is not, as of May 2026.
- The decision involves family-based behavioral support and pediatric monitoring.
If you are choosing between Wegovy and Zepbound:
- Zepbound produces more weight loss in trials.
- Wegovy has more cardiovascular and pediatric labeling.
- Insurance coverage, side-effect tolerance, and individual response factor into the choice.
If you are considering compounded semaglutide:
- Compounded semaglutide is not Wegovy and not FDA-approved.
- The compounding shortage pathway ended in February 2025.
- 503A personalized prescribing continues for specific clinical situations.
- Discuss with your provider whether compounded therapy fits your situation.
FAQ
Is Wegovy a GLP-1? Yes. Wegovy contains semaglutide, a pure GLP-1 receptor agonist.
What is Wegovy used for? Chronic weight management in adults with obesity or overweight with weight-related conditions. Cardiovascular risk reduction in adults with established CVD and overweight/obesity. Chronic weight management in adolescents 12 and older with BMI at or above the 95th percentile.
Is Wegovy the same as Ozempic? Same active ingredient (semaglutide). Different maximum dose (2.4 mg vs 2.0 mg), different titration schedule, different approved indications, different pen design.
How much weight do people lose on Wegovy? STEP 1 reported about 14.9 percent mean weight loss at 68 weeks. About one-third of patients lost 20 percent or more. Individual results vary.
Is Wegovy a dual agonist like Mounjaro? No. Wegovy is pure GLP-1. Mounjaro and Zepbound contain tirzepatide, a dual GLP-1/GIP agonist.
When was Wegovy approved? June 4, 2021, for chronic weight management. CV risk reduction added March 2024. Adolescent indication added December 2024.
Who makes Wegovy? Novo Nordisk, headquartered in Denmark.
Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide is not FDA-approved. It uses the same molecule but is prepared by 503A pharmacies under individual prescriptions.
What is the maximum dose of Wegovy? 2.4 mg subcutaneously once weekly. Patients titrate to this dose over four months.
Can I stop Wegovy after I reach my goal weight? STEP 4 showed substantial weight regain after discontinuation. Long-term use is generally required to maintain weight loss, similar to other chronic disease medications.
Does Wegovy work for diabetes? Semaglutide reduces HbA1c effectively. However, the FDA-approved semaglutide products for diabetes are Ozempic (injectable) and Rybelsus (oral). Wegovy for diabetes is off-label.
How much does Wegovy cost? Around $1,349 per month at list price. Novo Nordisk's self-pay program offers single-dose vials at approximately $499 per month for cash-paying patients.
Sources
- FDA Prescribing Information. Wegovy (semaglutide). Updated 2024.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg Once Weekly in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
- Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). New England Journal of Medicine. 2022.
- Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3). JAMA. 2021.
- Garvey WT et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nature Medicine. 2022.
- FDA Drug Shortages Database. Semaglutide Injection. 2022-2025.
- American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. 2023.
- Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that facilitates connections between consumers, independent licensed clinicians, and licensed U.S. pharmacies. We do not own a pharmacy, employ clinicians, or provide direct medical services. Clinical decisions are made by independent providers.
Compounded Medication Notice. Compounded semaglutide is not Wegovy. It is prepared by 503A compounding pharmacies under individual prescriptions and has not received FDA approval. The FDA has not reviewed compounded preparations for safety, purity, sterility, or efficacy.
Results Disclaimer. Trial averages reflect controlled study populations. Real-world outcomes depend on adherence, dose tolerance, dietary habits, activity levels, and individual biological response. Weight regain typically occurs after discontinuation.
Trademark Notice. Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Byetta and Bydureon are registered trademarks of AstraZeneca. FormBlends has no affiliation with Novo Nordisk, Eli Lilly, AstraZeneca, or any other manufacturer of these products.